Top 10 Companies in the (S)-1-(2-Fluorophenyl)Ethylamine Market (2026): Market Leaders Powering Global Chemistry

MARKET INSIGHTS

Global (S)-1-(2-Fluorophenyl)Ethylamine market size was valued at USD 28.4 million in 2025 and is projected to expand from USD 30.6 million in 2026 to USD 54.2 million by 2034, reflecting a growth trajectory of 6.6% over the forecast period.

(S)-1-(2-Fluorophenyl)Ethylamine Market – View in Detailed Research Report

(S)-1-(2-Fluorophenyl)Ethylamine is a chiral amine distinguished by a fluorine atom at the ortho position of the phenyl ring and the (S)-enantiomeric configuration. The compound is employed as a pivotal building block and chiral intermediate in the manufacture of active pharmaceutical ingredients (APIs), especially those targeting central nervous system (CNS) disorders. Its fluorinated scaffold confers metabolic stability and enhances membrane permeability, qualities that are highly prized in modern medicinal chemistry.

The demand for enantiopure intermediates, coupled with intensified research in chiral chemistry and a steadily growing pipeline of fluorine‑containing drug candidates, underpins the market’s upward momentum. Leading suppliers such as Sigma‑Aldrich (Merck KGaA), TCI Chemicals, and Fluorochem supply high‑purity chiral amine derivatives worldwide.

Top 10 Companies

1. Hairui Fine Chemical Co., Ltd.

Headquarters: Shanghai, China
Key Offering: Pharmaceutical‑grade (S)-1-(2‑Fluorophenyl)Ethylamine, high‑purity chiral intermediates for API synthesis

Hairui has established a reputation for consistent optical purity (>99% ee) and scalable production. The company’s ISO‑9001 and ISO‑14001 certifications underscore its commitment to quality and environmental stewardship. By integrating vertical supply chains, Hairui mitigates disruptions and secures raw material supply, a critical advantage in the high‑precision specialty chemical arena.

Sustainability & Growth Initiatives:

• Investment in continuous‑flow asymmetric hydrogenation to reduce solvent use
• Partnerships with regional pharma clusters to co‑develop custom intermediates
• Implementation of ISO 14001‑aligned waste‑management protocols

2. Capot Chemical Co., Ltd.

Headquarters: Shenzhen, China
Key Offering: Ultra‑high‑purity (>99.9% ee) chiral amines for CNS drug discovery

Capot’s state‑of‑the‑art chiral resolution facilities enable rapid turnaround for research and commercial batches. The firm’s strategic location in a major chemical hub facilitates timely delivery to global clients, while its focus on green chemistry aligns with evolving regulatory expectations.

Sustainability & Growth Initiatives:

• Adoption of bio‑based catalysts for asymmetric synthesis
• Development of modular synthesis modules for on‑demand production
• Engagement with academic institutions to pilot new chiral auxiliaries

3. Finetech Industry Limited

Headquarters: Tianjin, China
Key Offering: Custom chiral amine solutions for early‑stage R&D

Finetech’s flexible contract manufacturing model caters to small‑batch, high‑value projects. The company emphasizes rigorous analytical validation, ensuring that each lot meets stringent purity thresholds required by regulatory bodies.

Sustainability & Growth Initiatives:

• Integration of renewable energy sources in manufacturing plants
• Collaboration with CROs to streamline supply chain for academic projects
• Continuous improvement of chiral resolution efficiency through process analytics

4. Shanghai Trustin Chemical Co., Ltd.

Headquarters: Shanghai, China
Key Offering: High‑purity chiral intermediates for agrochemical and fine‑chemical sectors

Trustin’s diversified product portfolio extends beyond pharmaceuticals, capturing demand from agrochemical research that leverages fluorinated motifs for bioactivity. The company’s robust quality management system supports both regulatory compliance and product innovation.

Sustainability & Growth Initiatives:

• Implementation of closed‑loop water recycling in synthesis lines
• Participation in regional green chemistry consortiums
• Investment in high‑throughput screening for new chiral auxiliaries

5. SynQuest Laboratories, Inc.

Headquarters: San Diego, USA
Key Offering: Research‑grade chiral amines with rapid delivery for academic and early‑stage pharma projects

SynQuest’s cataloged inventory and on‑demand synthesis capabilities cater to the high‑volume needs of research institutions. The firm’s focus on analytical support and detailed synthetic route documentation enhances client confidence.

Sustainability & Growth Initiatives:

• Development of solvent‑free synthesis protocols
• Collaboration with university labs on green chemistry research
• Expansion of custom synthesis services for niche applications

6. Ningbo Inno Pharmchem Co., Ltd.

Headquarters: Ningbo, China
Key Offering: High‑purity chiral intermediates for CNS and antifungal drug development

Inno Pharmchem’s integrated manufacturing and R&D facilities enable rapid iteration of chiral synthesis routes. The company’s emphasis on process scalability positions it to meet the demands of both large‑scale API production and small‑batch R&D.

Sustainability & Growth Initiatives:

• Adoption of energy‑efficient catalytic systems
• Implementation of ISO 50001 for energy management
• Partnerships with CROs to accelerate lead optimization

7. Apollo Scientific Ltd.

Headquarters: London, UK
Key Offering: Custom chiral amine synthesis with cGMP compliance for pharma clients

Apollo Scientific combines advanced synthesis capabilities with stringent regulatory adherence. The firm’s track record in delivering cGMP‑qualified intermediates makes it a trusted partner for companies pursuing clinical‑grade manufacturing.

Sustainability & Growth Initiatives:

• Investment in green hydrogen production for catalytic processes
• Collaboration with EU regulatory bodies to streamline approval pathways
• Development of scalable chiral resolution modules

8. Enamine Ltd.

Headquarters: Kyiv, Ukraine
Key Offering: Research‑grade chiral amines for medicinal chemistry and synthetic biology projects

Enamine’s reputation for rapid synthesis and high purity supports academic and early‑stage industrial research. The company’s flexible order sizes cater to the dynamic needs of small laboratories.

Sustainability & Growth Initiatives:

• Implementation of solvent‑reduction strategies
• Partnerships with European research consortia
• Continuous improvement of chiral resolution efficiency

9. Shanghai Jiaoan Pharmaceutical Technology Co., Ltd.

Headquarters: Shanghai, China
Key Offering: High‑purity chiral intermediates for large‑scale API production

Jiaoan’s integrated production facilities and advanced chiral synthesis processes support large‑volume pharmaceutical manufacturing. The firm’s focus on quality assurance and regulatory compliance aligns with global pharma standards.

Sustainability & Growth Initiatives:

• Investment in renewable energy for manufacturing sites
• Implementation of zero‑waste initiatives in synthesis lines
• Collaboration with major pharma players for joint development projects

10. Sigma‑Aldrich (Merck KGaA)

Headquarters: Darmstadt, Germany
Key Offering: Comprehensive portfolio of chiral amines with cGMP certification

Sigma‑Aldrich’s global distribution network and extensive product catalog make it a go‑to source for high‑quality chiral intermediates. The company’s investment in asymmetric catalysis research underpins its leadership in the specialty chemical space.

Sustainability & Growth Initiatives:

• Adoption of bio‑based solvents across production lines
• Participation in the Circular Economy Initiative for chemicals
• Research on enzyme‑mediated chiral synthesis to reduce energy consumption

Download FREE Sample Report

Get Full Report

Outlook

The next decade will see a sustained expansion of the (S)-1-(2‑Fluorophenyl)Ethylamine market, driven by continued investment in CNS therapeutics and the adoption of advanced asymmetric synthesis techniques. As pharmaceutical companies intensify their focus on stereochemically defined molecules, the demand for high‑purity chiral intermediates will remain robust. Supply chain resilience will be reinforced by regional manufacturing hubs, particularly in Asia‑Pacific, which will continue to offer cost advantages while meeting stringent quality standards.

Future Trends

Emerging developments in biocatalysis and engineered transaminases promise to lower production costs and improve atom economy, potentially reshaping the competitive landscape. Parallel to this, the rise of contract research and development organizations (CROs) and contract development and manufacturing organizations (CDMOs) will amplify demand for reliable, high‑purity chiral building blocks. Finally, the growing emphasis on sustainability—through greener solvents, renewable energy, and waste‑reduction strategies—will become a decisive factor in supplier selection, pushing firms toward more environmentally responsible production methods.